Provided by Tiger Trade Technology Pte. Ltd.

Bio-Rad Laboratories

358.90
-8.6000-2.34%
Post-market: 358.900.00000.00%19:30 EST
Volume:182.30K
Turnover:65.73M
Market Cap:9.60B
PE:9.46
High:369.44
Open:364.34
Low:353.31
Close:367.50
52wk High:396.23
52wk Low:236.73
Shares:26.76M
Float Shares:22.50M
Volume Ratio:0.60
T/O Rate:0.81%
Dividend:- -
Dividend Rate:- -
EPS(TTM):37.95
EPS(LYR):27.85
ROE:14.27%
ROA:1.50%
PB:1.26
PE(LYR):12.89

Loading ...

Insight Molecular Diagnostics Presents GraftAssure Rollout Plans with Seven US Centers in Validation

Reuters
·
Nov 17

Press Release: Azora Therapeutics Reports 2026 Third Quarter Financial Results and Provides Business Update

Dow Jones
·
Nov 13

Bio-Rad EVP, General Counsel and Secretary Courtney C. Enloe Reports Sale of Common Shares Worth $348,320.83

Reuters
·
Nov 13

Bio Rad Laboratories (BIO) Stock Could Be 23% Overvalued Despite Activist Pressure

Simply Wall St.
·
Nov 10

Biodesix to Present New Molecular Residual Disease Testing Data at AMP 2026

Reuters
·
Nov 09

Bio Rad Laboratories (BIO) Could Be 14% Overvalued After Elliott Interest And Earnings

Simply Wall St.
·
Nov 09

Is Revenue Growth Return Altering The Investment Case For Bio Rad Laboratories (BIO)?

Simply Wall St.
·
Nov 07

The Bio-Rad Laboratories, Inc. (NYSE:BIO) Third-Quarter Results Are Out And Analysts Have Published New Forecasts

Simply Wall St.
·
Nov 06

US Research Roundup-Cencora, Dave, Uber

Reuters
·
Nov 05

Bio-Rad Laboratories, Inc. : Jefferies Raises Target Price to $350 from $335

THOMSON REUTERS
·
Nov 05

Bio-Rad Laboratories, Inc. Reports Results for the Quarter Ended September 30 - Earnings Summary

Reuters
·
Nov 05

Bio-Rad's Q3 Revenue Comes Slightly Above Estimates on Clinical Diagnostics Growth

Reuters
·
Nov 05

Bio-Rad Swings to Q3 2026 Net Income of $458.6 Million

Reuters
·
Nov 05

Bio-Rad Q3 EBIT Margin -7.6%

Reuters
·
Nov 05

Bio-Rad Q3 Gross Margin 50.1%

THOMSON REUTERS
·
Nov 05

Bio-Rad Outlook FY Adjusted Revenue Growth -3 to 0.5%

THOMSON REUTERS
·
Nov 05

Bio-Rad Q3 Sales USD 656.4 Million

THOMSON REUTERS
·
Nov 05

Bio-Rad CFO to Participate in Fireside Chat at UBS Global Healthcare Conference

Reuters
·
Oct 30

Earning Preview: Bio-Rad Laboratories Q3 revenue is expected to decrease by 0.21%, and institutional views are cautiously bullish

Earnings Agent
·
Oct 28

Bell Potter Keeps Their Buy Rating on Biome Australia Ltd (BIO)

TIPRANKS
·
Oct 27